
Fibrin glue-assisted posterior IOL implantation is a beneficial technique for clinical indications such as dislocated nucleus, dislocated IOL, or subluxated cataract.
Fibrin glue-assisted posterior IOL implantation is a beneficial technique for clinical indications such as dislocated nucleus, dislocated IOL, or subluxated cataract.
The use of a toric IOL corrects low levels of preoperative astigmatism in patients undergoing cataract surgery.
Results from 3 years of follow-up in patients with the dual-optic accommodating IOL implanted bilaterally show this second-generation accommodating technology provides adequate and stable functional vision at all distances.
Results of a study comparing 1- and 3-piece models of the anterior surface modified prolate hydrophobic acrylic IOL show excellent capsule bag performance of both implants.
The +3.0-D add version of the apodized diffractive multifocal IOL provides a high rate of spectacle independence.
Results of retrospective analyses refute an association between relative humidity in the operating room and LASIK refractive outcomes.
After years of wrangling in court with two former regional manufacturer's representatives, officials at STAAR Surgical Co. hope a $4 million settlement will allow it to move forward with new products and solidify its financial status.
LenSx Lasers Inc. announced it received FDA clearance of its proprietary femtosecond laser technology for use in performing phacofragmentation during cataract surgery.
The American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery are among 25 groups urging Congress to solve the Medicare physician payment problem.
While perusing the abstract book for an upcoming ophthalmology meeting, the author came across an intriguing title.
Proper specialized instrumentation and a dispersive ophthalmic viscosurgical device are integral to the success of explantation and exchange of multifocal IOLs.
Advances in technology have changed the way we do business greatly.
J&J Vision Care may continue selling its Acuvue Oasys contact lenses even though their manufacturing infringes CIBA Vision's patent, in order to protect "millions of innocent contact lens wearers" who would have to be refitted with a different brand, a federal judge has ruled.
An accommodating IOL offers excellent depth of focus and quality of vision with reduced dependence on glasses.
With the FDA clearance of a new monofocal pseudophakic posterior chamber IOL comes the availability of a novel implant designed with a host of features that result in outstanding outcomes and that make the lens a premier option for most cataract surgery patients.
The FDA has granted 510(k) clearance to a hybrid mydriatic/non-mydriatic digital retinal camera (CX-1, Canon).
Reichert Inc. has unveiled a new brand name and redesigned visual identity, Reichert Technologies.
The first femtosecond-only method of laser vision correction is now able to be performed outside the United States after several years of clinical research and development, according to the manufacturer of the laser with which it is performed (VisuMax, Carl Zeiss Meditec).
An accommodating IOL with aspheric optics (Crystalens AO, Bausch + Lomb) has received new-technology IOL classification from the Centers for Medicare and Medicaid Services.
A thermo-biomechanical system (Vedera, Avedro) for performing a proprietary procedure (Keraflex) to flatten the cornea in the treatment of myopia and keratoconus has received the European Union (EU) CE mark.
The FDA has granted 510(k) clearance to a femtosecond laser (LenSx, LenSx Lasers Inc.) for use in cataract surgery. Specifically, the device is used for laser phacofragmentation.
Ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) is now commercially available for the treatment of acute herpetic keratitis
The FDA has approved a new IOL (Softec HD, Lenstec) for patients with cataracts.
Congress again has delayed a 21% Medicare physician payment cut, this time until June 1.
Concern about potential long-term toxicity associated with use of mitomycin-C is driving researchers to identify new pharmacologic approaches for managing haze formation after PRK.
Analyses of 24-month data from the two pivotal phase III trials investigating a proprietary fluocinolone acetonide-releasing intravitreal insert for the treatment of diabetic macular edema generated positive results that are the basis of filing a new drug application with the FDA.
Six hours of occlusive therapy and treatment with atropine can be beneficial to children with severe amblyopia.
Of all the ophthalmology programs in the United States, the Bascom Palmer Eye Institute at the Unviersity of Miami Miller School of Medicine is among the youngest.
Nanotechnology is the newest and perhaps most exciting and futuristic application in ophthalmology.